REGENXBIO Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed February 28, 2023. REGENXBIO is a clinical-stage gene therapy company developing AAV-based therapies and licensing its NAV platform. It has no product sales of its own; revenue comes from licenses and royalties.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $112.7 million | $470.3 million |
| Operating expenses | $375.6 million | $310.4 million |
| Operating income (loss) | $(262.9) million | $160.0 million |
| Net income (loss) | $(280.3) million | $127.8 million |
| Operating cash flow | $(207.5) million | $218.9 million |
| Cash, cash equivalents and marketable securities | $565.2 million | $849.3 million |
- Revenue fell 76% year over year, principally because FY2021 included a nonrecurring $370.0 million AbbVie upfront payment. Zolgensma royalties rose to $101.9 million from $95.0 million.
- R&D expense increased 34% to $242.5 million, reflecting clinical-trial and manufacturing investment, partly offset by AbbVie reimbursements. The company reported no product gross margin; cost of revenues was $54.5 million.
- Cash and investments declined by $284.1 million. Management said available resources were expected to fund operations and capital needs for at least 12 months from the report date, based on its current plan. Current assets were $416.0 million and current liabilities $130.4 million.
- Debt-like financing: the liability from selling future Zolgensma royalties to HCR was $137.6 million at year-end ($48.6 million current). The company has no obligation to repay HCR if royalties are insufficient. Operating lease liabilities totaled $94.8 million.
Material changes and notable items
- The 2022 net loss contrasts with FY2021 profit, which was heavily supported by the AbbVie upfront payment. R&D and general and administrative expenses rose to $242.5 million and $85.3 million, respectively.
- REGENXBIO recorded a $9.2 million charge related to its Penn license amendment, which replaced future sublicense-fee obligations with $20.0 million of payments. A $7.5 million third-party settlement payment was recorded as other operating income.
- One customer, Novartis Gene Therapies, represented approximately 90% of FY2022 revenue. Revenue remains dependent on a limited number of licensees and royalties.
Outlook, programs and principal risks
- RGX-314: AbbVie became responsible for the majority of development expenses beginning January 1, 2023. Subretinal wet-AMD pivotal trials were enrolling; the company expected to support a BLA submission in 2024. FY2022 interim trial updates reported generally favorable tolerability and reduced anti-VEGF treatment burden, but findings are preliminary.
- RGX-121: The company expected to complete enrollment of 10 pivotal-program patients in the first half of 2023 and aimed to support a 2024 BLA filing through accelerated approval. The filing reports positive interim biomarker and clinical observations announced in February 2023, after year-end.
- Other pipeline: Initial RGX-202 trial data were expected in the second half of 2023; RGX-381’s first-in-human trial was expected to begin in the first half of 2023. Management’s longer-term goal was multiple therapies FDA-approved or in pivotal trials by the end of 2025; it cautioned that milestones may slip or not be achieved.
- Key risks include clinical or regulatory failure and delays, gene-therapy safety and durability uncertainty, manufacturing scale-up and supply constraints, competition, reimbursement and pricing uncertainty, dependence on partners and concentrated royalty revenue, intellectual-property disputes, and the need for additional capital. The company expects operating losses for at least several years and has never generated revenue from its own product sales.
- The company reported no material pending legal proceeding and no off-balance-sheet arrangements. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether cash burn, trial spending and the stated runway remain consistent with the company’s financing needs and updated plans.
- Progress, safety, efficacy and regulatory feedback for RGX-314 and RGX-121, including whether the projected 2024 BLA timelines remain achievable.
- Future Zolgensma sales and royalties, the HCR repayment cap and timing, and the effect of customer concentration on revenue.
- Whether AbbVie meets its development and cost-sharing commitments and how collaboration economics evolve.
- Potential dilution or other financing, plus manufacturing readiness and reimbursement prospects for any future approved therapy.